Cancer
| 6 min read
ArsenalBio equips T cells with multiple weapons to identify, attack, and persist against tumors, bringing the power of CAR T cell technology to solid cancers.
| 6 min read
Judy Sebolt-Leopold and her team at MEKanistic Therapeutics developed a single molecule targeting two kinase enzymes that drive resistance to cancer therapies.
| 6 min read
Most cancer cells have the wrong number of chromosomes, known as aneuploidy. Scientists are finding ways to target this flaw with new treatments.
| 2 min read
New animal research suggests that the risk of developing cancer might be decided early in life.
| 2 min read
Researchers revealed for the first time that CAR T cells can transfer their CAR molecules to regular T cells in a process known as trogocytosis.
| 4 min read
Pfizer researchers are developing new treatments to target breast cancer tumors that flourish in the presence of hormones.
Available on Demand
Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
| 3 min read
Ovarian tumors are extremely difficult to get rid of. Scientists are figuring out how to leverage the immune system to help.
| 3 min read
An immune checkpoint inhibitor and chemotherapy extended progression-free survival in late-stage small cell bladder and prostate cancers.
| 4 min read
Mesenchymal stem cells form nanotubes with and donate mitochondria to T cells, boosting the immune cells’ cancer fighting abilities.
| 3 min read
Two mutations in the BRCA1 gene greatly increase the risk of breast cancer. Now, it seems that only one mutation can help cells tip toward a cancerous edge.
| 4 min read
Industry leaders name the clinical trials and developments they’re most excited to see in the new year.
